AbbVie Inc. shares moved higher in pre-market activity, trading up about 0.8% after BMO Capital Markets issued a strongly positive analyst note that lifted the firm's price target to $300 from $258 and reaffirmed an Outperform rating.
In its note, BMO emphasized that Skyrizi has maintained revenue durability through the second quarter of 2026. The firm said the drug has so far faced limited competitive pressure even after the first-quarter approval and commercial introduction of a rival therapy, Icotyde.
The BMO action follows a series of recent price-target raises from other major Wall Street firms. RBC Capital, Wells Fargo, Bank of America, HSBC and Cantor Fitzgerald have all issued higher targets in recent days, with each firm pointing to strength in AbbVie's immunology franchise as a central driver of their revisions.
Investor attention is concentrated on several near-term corporate events. AbbVie’s Q2 2026 earnings call is scheduled for July 31. In addition, the company’s quarterly dividend of $1.73 per share has an ex-dividend date set for July 15 - a scheduled distribution that typically draws focus from income-oriented shareholders.
Market conditions outside the company are providing a modest supportive tone. U.S. equity futures were pointing up as market participants weighed signs of cooling global inflation ahead of a consequential week of events. While there was no major domestic economic data scheduled on the day in question, the release of June CPI figures and Federal Reserve Chairman Kevin Warsh’s first congressional testimony on monetary policy were set for the following day, leaving rate-sensitive sectors attentive to incoming information.
Taken together, renewed analyst conviction around Skyrizi’s competitive positioning, an upcoming earnings call and the impending dividend ex-date, combined with a mildly positive macro backdrop, helped lift AbbVie shares in pre-market trade. The stock was trading toward the higher end of its recent range but remained below its 52-week high of $261.64.
Key points
- BMO Capital raised its price target on AbbVie to $300 from $258 and maintained an Outperform rating, citing Skyrizi’s revenue durability through Q2 2026.
- Multiple Wall Street firms including RBC Capital, Wells Fargo, Bank of America, HSBC and Cantor Fitzgerald have recently increased price targets, noting strength in AbbVie’s immunology franchise.
- Near-term catalysts include the Q2 2026 earnings call on July 31 and the $1.73 quarterly dividend with a July 15 ex-date; macro developments such as June CPI and the Fed chair’s testimony are also keeping markets sensitive.
Risks and uncertainties
- Competitive dynamics for Skyrizi remain an uncertainty - while BMO notes limited pressure so far, future competition could affect revenue trends; this particularly affects the pharmaceutical and healthcare sectors.
- Macroeconomic and policy developments, including upcoming CPI data and the Fed chairman’s congressional testimony, create rate-sensitive market risk that could influence investor appetite for AbbVie and similar dividend-paying stocks.
- Near-term price volatility is possible around the company’s Q2 2026 earnings call and the dividend ex-date, which could affect equity market sectors focused on healthcare and income strategies.
Note: This article reports on analyst actions, upcoming company events and market conditions as described above. It does not introduce additional data or analysis beyond those items.